337 related articles for article (PubMed ID: 32623935)
1. Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression.
Rangarajan S; Richter JR; Richter RP; Bandari SK; Tripathi K; Vlodavsky I; Sanderson RD
J Histochem Cytochem; 2020 Dec; 68(12):823-840. PubMed ID: 32623935
[TBL] [Abstract][Full Text] [Related]
2. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.
Purushothaman A; Uyama T; Kobayashi F; Yamada S; Sugahara K; Rapraeger AC; Sanderson RD
Blood; 2010 Mar; 115(12):2449-57. PubMed ID: 20097882
[TBL] [Abstract][Full Text] [Related]
3. Heparanase regulates levels of syndecan-1 in the nucleus.
Chen L; Sanderson RD
PLoS One; 2009; 4(3):e4947. PubMed ID: 19305494
[TBL] [Abstract][Full Text] [Related]
4. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.
Yang Y; Macleod V; Miao HQ; Theus A; Zhan F; Shaughnessy JD; Sawyer J; Li JP; Zcharia E; Vlodavsky I; Sanderson RD
J Biol Chem; 2007 May; 282(18):13326-33. PubMed ID: 17347152
[TBL] [Abstract][Full Text] [Related]
5. Heparanase-Regulated Syndecan-1 Shedding Facilitates Herpes Simplex Virus 1 Egress.
Hadigal S; Koganti R; Yadavalli T; Agelidis A; Suryawanshi R; Shukla D
J Virol; 2020 Feb; 94(6):. PubMed ID: 31827001
[TBL] [Abstract][Full Text] [Related]
6. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway.
Yu S; Lv H; Zhang H; Jiang Y; Hong Y; Xia R; Zhang Q; Ju W; Jiang L; Ou G; Zhang J; Wang S; Zhang J
Biochem Biophys Res Commun; 2017 Apr; 485(2):432-439. PubMed ID: 28209511
[TBL] [Abstract][Full Text] [Related]
7. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.
Ramani VC; Purushothaman A; Stewart MD; Thompson CA; Vlodavsky I; Au JL; Sanderson RD
FEBS J; 2013 May; 280(10):2294-306. PubMed ID: 23374281
[TBL] [Abstract][Full Text] [Related]
8. Biology of the Heparanase-Heparan Sulfate Axis and Its Role in Disease Pathogenesis.
Vlodavsky I; Barash U; Nguyen HM; Yang SM; Ilan N
Semin Thromb Hemost; 2021 Apr; 47(3):240-253. PubMed ID: 33794549
[TBL] [Abstract][Full Text] [Related]
9. Heparanase Mediates Intestinal Inflammation and Injury in a Mouse Model of Sepsis.
Chen S; He Y; Hu Z; Lu S; Yin X; Ma X; Lv C; Jin G
J Histochem Cytochem; 2017 Apr; 65(4):241-249. PubMed ID: 28170292
[TBL] [Abstract][Full Text] [Related]
10. Heparan sulfate chains of syndecan-1 regulate ectodomain shedding.
Ramani VC; Pruett PS; Thompson CA; DeLucas LD; Sanderson RD
J Biol Chem; 2012 Mar; 287(13):9952-9961. PubMed ID: 22298773
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Syndecan-1 and Heparanase in Cancer and Inflammation.
Teixeira FCOB; Götte M
Adv Exp Med Biol; 2020; 1221():97-135. PubMed ID: 32274708
[TBL] [Abstract][Full Text] [Related]
12. Genesis of placental sequestration in malaria and possible targets for drugs for placental malaria.
Clark RL
Birth Defects Res; 2019 Jun; 111(10):569-583. PubMed ID: 30919596
[TBL] [Abstract][Full Text] [Related]
13. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype.
Purushothaman A; Hurst DR; Pisano C; Mizumoto S; Sugahara K; Sanderson RD
J Biol Chem; 2011 Sep; 286(35):30377-30383. PubMed ID: 21757697
[TBL] [Abstract][Full Text] [Related]
14. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y
Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720
[TBL] [Abstract][Full Text] [Related]
15. Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis.
Kelly T; Suva LJ; Nicks KM; MacLeod V; Sanderson RD
J Bone Miner Res; 2010 Jun; 25(6):1295-304. PubMed ID: 20200931
[TBL] [Abstract][Full Text] [Related]
16. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
17. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
Mikami S; Ohashi K; Usui Y; Nemoto T; Katsube K; Yanagishita M; Nakajima M; Nakamura K; Koike M
Jpn J Cancer Res; 2001 Oct; 92(10):1062-73. PubMed ID: 11676857
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B; Yang Y
Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
[TBL] [Abstract][Full Text] [Related]
19. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.
Purushothaman A; Chen L; Yang Y; Sanderson RD
J Biol Chem; 2008 Nov; 283(47):32628-36. PubMed ID: 18812315
[TBL] [Abstract][Full Text] [Related]
20. Heparanase: busy at the cell surface.
Fux L; Ilan N; Sanderson RD; Vlodavsky I
Trends Biochem Sci; 2009 Oct; 34(10):511-9. PubMed ID: 19733083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
